On June 4, UnitedHealth rose 4.29% in regular trading, trading at $395.23/share, with trading volume of $533 million.

On the news front, Bank of America upgraded UnitedHealth from Neutral to Buy, raising its target price from $420 to $450, implying approximately 14% upside from the current level. The upgrade was primarily driven by improving medical cost trends and a favorable setup ahead of the Q2 earnings report. Additionally, Truist raised its target from $395 to $440 while maintaining a Buy rating, and Oppenheimer lifted its target from $405 to $420.

Fundamentally, April and May medical utilization data continued to trend favorably, suggesting that earnings improvement is sustainable rather than driven by one-time factors such as flu season or extreme weather. Meanwhile, subsidiary UnitedHealthcare announced plans to eliminate approximately two-thirds of prior authorization requirements for members under 18 by year-end, a move expected to enhance operational efficiency and patient satisfaction.

Within the Managed Health Care sector, peers also posted gains: Centene up 3.83%, Humana up 3.54%, Molina Healthcare up 3.19%, Elevance Health up 2.99%, and Alignment Healthcare up 5.26%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)